136 related articles for article (PubMed ID: 8562934)
21. Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8
Powell RM; Peeters MJW; Rahbech A; Aehnlich P; Seremet T; Thor Straten P
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835225
[TBL] [Abstract][Full Text] [Related]
22. The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.
Al-Subaie AM; Kamaraj B
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299222
[TBL] [Abstract][Full Text] [Related]
23. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.
Wang J; Ma J; Cai C; Daver N; Ning J
Stat Med; 2021 Sep; 40(21):4629-4639. PubMed ID: 34101217
[TBL] [Abstract][Full Text] [Related]
24. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression.
Zhang D; Guo Y; Zhao Y; Yu L; Chang Z; Pei H; Huang J; Chen C; Xue H; Xu X; Pan Y; Li N; Zhu C; Zhao ZJ; Yu J; Chen Y
Microb Cell Fact; 2021 Mar; 20(1):67. PubMed ID: 33691697
[TBL] [Abstract][Full Text] [Related]
25. Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.
K Bhanumathy K; Balagopal A; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Giambra V
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430292
[TBL] [Abstract][Full Text] [Related]
26.
Kennedy VE; Smith CC
Front Oncol; 2020; 10():612880. PubMed ID: 33425766
[TBL] [Abstract][Full Text] [Related]
27. Potential targeting of FLT3 acute myeloid leukemia.
Ambinder AJ; Levis M
Haematologica; 2021 Mar; 106(3):671-681. PubMed ID: 32703795
[TBL] [Abstract][Full Text] [Related]
28. Identification the prognostic value of glutathione peroxidases expression levels in acute myeloid leukemia.
Wei J; Xie Q; Liu X; Wan C; Wu W; Fang K; Yao Y; Cheng P; Deng D; Liu Z
Ann Transl Med; 2020 Jun; 8(11):678. PubMed ID: 32617298
[TBL] [Abstract][Full Text] [Related]
29. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
Yeung YA; Krishnamoorthy V; Dettling D; Sommer C; Poulsen K; Ni I; Pham A; Chen W; Liao-Chan S; Lindquist K; Chin SM; Chunyk AG; Hu W; Sasu B; Chaparro-Riggers J; Djuretic I
Mol Ther; 2020 Mar; 28(3):889-900. PubMed ID: 31981494
[TBL] [Abstract][Full Text] [Related]
30. Scalable Prediction of Acute Myeloid Leukemia Using High-Dimensional Machine Learning and Blood Transcriptomics.
Warnat-Herresthal S; Perrakis K; Taschler B; Becker M; Baßler K; Beyer M; Günther P; Schulte-Schrepping J; Seep L; Klee K; Ulas T; Haferlach T; Mukherjee S; Schultze JL
iScience; 2020 Jan; 23(1):100780. PubMed ID: 31918046
[TBL] [Abstract][Full Text] [Related]
31. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract][Full Text] [Related]
32. Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia.
Seipel K; Schmitter K; Bacher U; Pabst T
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31718075
[TBL] [Abstract][Full Text] [Related]
33. Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia.
Raeisi M; Nikhanfar AR; Nejate B; Movassaghpour Akbari AA; Dolatkhah R; Roosta Y; Sanaat Z
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2625-2631. PubMed ID: 31554356
[TBL] [Abstract][Full Text] [Related]
34. Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies.
Handschuh L
J Oncol; 2019; 2019():7239206. PubMed ID: 31467542
[TBL] [Abstract][Full Text] [Related]
35. A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology.
Skayneh H; Jishi B; Hleihel R; Hamieh M; Darwiche N; Bazarbachi A; El Sabban M; El Hajj H
Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31412687
[TBL] [Abstract][Full Text] [Related]
36. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Daver N
Ther Adv Hematol; 2019; 10():2040620719827310. PubMed ID: 30800259
[TBL] [Abstract][Full Text] [Related]
37. FLT3, a prognostic biomarker for acute myeloid leukemia (AML): Quantitative monitoring with a simple anti-FLT3 interaction and flow cytometric method.
Ampasavate C; Jutapakdee W; Phongpradist R; Tima S; Tantiworawit A; Charoenkwan P; Chinwong D; Anuchapreeda S
J Clin Lab Anal; 2019 May; 33(4):e22859. PubMed ID: 30737839
[TBL] [Abstract][Full Text] [Related]
38. Direct role of FLT3 in regulation of early lymphoid progenitors.
Zriwil A; Böiers C; Kristiansen TA; Wittmann L; Yuan J; Nerlov C; Sitnicka E; Jacobsen SEW
Br J Haematol; 2018 Nov; 183(4):588-600. PubMed ID: 30596405
[TBL] [Abstract][Full Text] [Related]
39. Clinical use of FLT3 inhibitors in acute myeloid leukemia.
Sutamtewagul G; Vigil CE
Onco Targets Ther; 2018; 11():7041-7052. PubMed ID: 30410361
[TBL] [Abstract][Full Text] [Related]
40. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
